GLA and Fabry disease: Since 2001, enzyme replacement therapy (ERT) is available for the treatment of Fabry disease when the indications for treatment are met, either with agalsidase-alfa (0.2 mg/kg/2 weeks) or agalsidase-beta (1.0 mg/kg/2 weeks) [12].